ECT2 and adenoma: ECT2 was identified as overexpressed in adenomas and CRC, elevated nucleated ECT2 correlated with poorly differentiated tumors, a low cytoplasmic to nuclear ratio of ECT2 was associated with poor patient survival and suggests that this gene is a driver of tumor progression [70].